◀ Back to CD79A

CD79A — VEGFA

Text-mined interactions from Literome

Mayerhofer et al., Blood 2002 : BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin ... We show here that the CML associated oncogene BCR/ABL induces VEGF gene expression in growth factor dependent Ba/F3 cells ... BCR/ABL induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase ( PI3-kinase ) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen activated protein kinase pathway
Ebos et al., Mol Cancer Res 2002 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive...) : Imatinib mesylate ( STI-571 ) reduces Bcr-Abl mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia ... Transfection of BCR-ABL into murine myeloid 32D and human megakaryocyte MO7e hematopoietic cells resulted in enhanced VEGF expression, which could be further elevated by the exposure to cytokines such as interleukin 3 and granulocyte macrophage colony stimulating factor
Li et al., J Int Med Res 2009 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Studies have shown that vascular endothelial growth factor ( VEGF ), a major and potent inducer of angiogenesis, is directly triggered by the disease related oncogene Bcr-Abl in Bcr-Abl positive cells
Maiolini et al., BMC veterinary research 2013 (Arteritis...) : To investigate if transforming growth factor beta 1 ( TGF-ß1 ), interleukin-6 (IL-6) and vascular endothelial growth factor ( VEGF ) are involved in the production of excessive immunoglobulin A (IgA) , the induction of acute phase proteins and in the development of a systemic necrotizing vasculitis, characteristic of SRMA, these three signalling proteins were evaluated